merged_alzheimers-treatment-kisunla-donanemab.txt
<other>First, I will analyze the article to find relevant information for each question.</other>
<question_number>1</question_number>
<answer>The primary reason for skepticism is that the drug's benefits may not be noticeable to patients or families, and some experts believe the risks outweigh the modest benefits.</answer>
<question_number>2</question_number>
<answer>The article suggests that the focus on anti-amyloid drugs might discourage patients from participating in trials for potentially better treatments, thereby slowing overall progress in Alzheimer's research.</answer>
<question_number>3</question_number>
<answer>Dr. Greicius describes the relationship by stating there is no correlation between the removal of amyloid plaques and the clinical response in individual subjects, which raises questions about the drug's effectiveness.</answer>
<question_number>4</question_number>
<answer>The higher rates of swelling and bleeding in the donanemab trial compared to the Leqembi trial could negatively impact the perception of Kisunla's safety, as it indicates a higher risk of serious side effects.</answer>
<question_number>5</answer>
<answer>The article suggests that the cost of Kisunla might be justified because patients can stop the drug after their amyloid plaques are cleared, potentially reducing the overall cost, inconvenience, and risk of side effects compared to Leqembi.</answer>
<question_number>6</question_number>
<answer>The article suggests that the emphasis on anti-amyloid drugs might discourage patients from participating in trials for other treatments, as they might prefer to stick with the approved drugs despite their modest benefits.</answer>
<question_number>7</question_number>
<answer>The article explains that Kisunla can potentially reduce the inconvenience of treatment compared to Leqembi because patients can stop taking Kisunla once their amyloid plaques are cleared, whereas Leqembi requires continuous dosing.</answer>
<question_number>8</question_number>
<answer>Kisunla targets amyloid, the clearance of which allows patients to potentially discontinue treatment.</answer>
<question_number>9</question_number>
<answer>Dr. Michael Greicius criticized the lack of correlation between amyloid plaque removal and clinical response in individual subjects for anti-amyloid drugs.</answer>
<question_number>10</question_number>
<answer>The factor suggesting that treating patients earlier might be more effective is the donanemab trial's finding that participants with intermediate tau levels declined more slowly on the drug than those with high levels.</answer>